BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 35816445)

  • 1. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction.
    Stepan H; Galindo A; Hund M; Schlembach D; Sillman J; Surbek D; Vatish M
    Ultrasound Obstet Gynecol; 2023 Feb; 61(2):168-180. PubMed ID: 35816445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of angiogenic markers in pregnancy with fetal growth restriction.
    Palmrich P; Kalafat E; Pateisky P; Schirwani-Hartl N; Haberl C; Herrmann C; Khalil A; Binder J
    Ultrasound Obstet Gynecol; 2024 May; 63(5):619-626. PubMed ID: 37774098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia.
    Binder J; Palmrich P; Kalafat E; Haberl C; Schirwani N; Pateisky P; Khalil A
    Ultrasound Obstet Gynecol; 2023 Dec; 62(6):843-851. PubMed ID: 37265117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental growth factor and fetoplacental Doppler indices in combination predict preterm birth reliably in pregnancies complicated by fetal growth restriction.
    Hong J; Crawford K; Cavanagh E; da Silva Costa F; Kumar S
    Ultrasound Obstet Gynecol; 2024 May; 63(5):635-643. PubMed ID: 37820083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenic imbalance in pre-eclampsia and fetal growth restriction: enhanced soluble fms-like tyrosine kinase-1 binding or diminished production of placental growth factor?
    Kluivers ACM; Biesbroek A; Visser W; Saleh L; Russcher H; Danser AHJ; Neuman RI
    Ultrasound Obstet Gynecol; 2023 Apr; 61(4):466-473. PubMed ID: 36191149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal change of sFlt-1/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction.
    Herraiz I; Quezada MS; Rodriguez-Calvo J; Gómez-Montes E; Villalaín C; Galindo A
    Ultrasound Obstet Gynecol; 2018 Nov; 52(5):631-638. PubMed ID: 28876491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
    Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
    J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
    Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
    Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ophthalmic artery Doppler and biomarkers of impaired placentation at 36 weeks' gestation in pregnancies with small fetuses.
    Arechvo A; Wright A; Nobile Recalde A; Liandro R; Charakida M; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 Mar; 63(3):358-364. PubMed ID: 37902727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of hypertensive disorders after screening at 36 weeks' gestation: comparison of angiogenic markers with competing-risks model.
    Schiattarella A; Magee LA; Wright A; Syngelaki A; Akolekar R; Von Dadelszen P; Nicolaides KH
    Ultrasound Obstet Gynecol; 2023 Sep; 62(3):345-352. PubMed ID: 37329494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. sFlt-1 to PlGF ratio cut-offs to predict adverse pregnancy outcomes in early-onset FGR and SGA: a prospective observational study.
    Bonacina E; Armengol-Alsina M; Hurtado I; Garcia-Manau P; Ferrer-Oliveras R; Monreal S; Pancorbo M; Mendoza M; Carreras E
    J Obstet Gynaecol; 2022 Oct; 42(7):2840-2845. PubMed ID: 35980876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation.
    Sokratous N; Wright A; Syngelaki A; Kakouri E; Laich A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 Jan; 63(1):88-97. PubMed ID: 37724582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study.
    Herraiz I; Simón E; Gómez-Arriaga PI; Quezada MS; García-Burguillo A; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2018 Jul; 13():279-285. PubMed ID: 30177066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation.
    Litwinska M; Litwinska E; Astudillo A; Syngelaki A; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):360-368. PubMed ID: 33794058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.
    Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies.
    Dröge L; Herraìz I; Zeisler H; Schlembach D; Stepan H; Küssel L; Henrich W; Galindo A; Verlohren S
    Ultrasound Obstet Gynecol; 2015 Mar; 45(3):286-93. PubMed ID: 25491901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study.
    Sabriá E; Lequerica-Fernández P; Lafuente-Ganuza P; Eguia-Ángeles E; Escudero AI; Martínez-Morillo E; Barceló C; Álvarez FV
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):758-767. PubMed ID: 29498431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.